Dr. Spencer Nadolsky joins Ethan on the American Glutton Podcast to dive into the revolutionary impact of GLP-1 drugs on obesity and cardiometabolic health, exploring their benefits, risks, and societal implications. From debunking myths about weight loss to discussing emerging treatments like myostatin inhibitors, they tackle the science and real-world applications head-on. The conversation also touches on the future of these medications, their potential to prevent weight gain, and the importance of combining them with lifestyle changes like resistance training. SHOW HIGHLIGHTS 00:00 - Introduction and Catching Up 00:35 - Obesity as a Choice and GLP-1 Drugs 01:58 - Misuse of GLP-1s and Social Media Hype 05:08 - The Science Behind GLP-1 and Incretin Effect 07:37 - How GLP-1 Drugs Work for Weight Loss 10:00 - Benefits vs. Risks of GLP-1 Drugs 11:57 - Common Side Effects and Nausea Discussion 13:15 - Fatigue and Anhedonia as Side Effects 14:54 - Fat Cell Memory and Weight Regain 17:41 - GLP-1s as a Breakthrough for Obesity 19:33 - Comparing Risks of GLP-1s to Other Drugs 20:24 - Big Pharma and Advisory Boards 23:57 - Importance of Protein and Resistance Training 27:34 - Myostatin Inhibitors and Muscle Growth 31:39 - Timeline for New Drug Approvals 33:31 - Drug Costs and Accessibility 37:51 - Comparing GLP-1 Drugs and Zepbound 39:57 - Glucagon and Triple Agonist Drugs 41:58 - Future of GLP-1s in Preventing Weight Gain 43:43 - Microdosing and Anti-Inflammatory Effects 44:33 - GLP-1s and Type 1 Diabetes Considerations 48:50 - Historical Context and Obesity Trends 52:37 - Moralizing Weight and Pharmaceutical Solutions 54:03 - Closing Thoughts and Future Support Hosted on Acast. See acast.com/privacy for more information.
